Loading organizations...
§ Venture Capital · Shanghai, China
Venture capital firm investing in pharmaceutical and biotechnology startups, supporting biomedical innovation globally from China.
Hankang Capital is a venture capital firm based in Shanghai, China, specializing in investments within the pharmaceutical and biotechnology sectors. The firm is dedicated to supporting biomedical innovation with a global vision, actively empowering healthcare startups through both funding and strategic partnerships. Their investment focus spans critical therapeutic areas such as oncology and ADC therapeutics, aiming to advance novel treatments and technologies that address unmet medical needs. Key personnel contributing to the firm's investment strategy include Managing Director Chloe Chen, Vice President of Investment Pengchong Wang, and Senior Advisor Rui Zhao. Hankang Capital works to enable its portfolio companies to navigate complex development pathways and achieve market success in a competitive landscape. The firm was established in 2010; its founder is unknown.
Hankang Capital has 1 tracked investment across 1 company. The latest tracked deal is $35.0M Seed in Spurious in January 2026.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Jan 30, 2026 | Spurious | $35.0M Seed | Highlight Capital | Biotrack Capital, InnoPinnacle Fund, Lichen Capital, LongRiver Investments |